Trial · NCT07569757
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
NCT07569757, Phase 3, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma. Trials, record NCT07569757. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07569757
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- NCT number
- NCT07569757
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 260 participants, estimated
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions
- Multiple Myeloma
- Interventions
- TQB2934 injection, Pomalidomide Capsule, Selinexor tablets, Dexamethasone tablets
- First posted
- 2026-05-06
- Last updated
- 2026-05-08
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Baseline up to 5 years | The time from randomization to disease progression or death from any cause, whichever occurs first. |
| Secondary | Investigator-assessed PFS | Baseline up to 5 years | The time from randomization to disease progression or death from any cause, whichever comes first. |
| Secondary | PFS rates at 6, 12 and 18 months | From baseline to 18 months | The proportion of patients who remain free from disease progression or death at 6, 12 and 18 months after randomization. |
| Secondary | Overall response rate (ORR) | Baseline up to 5 years | The proportion of patients with a complete response (CR) or partial response (PR) after treatment. |
| Secondary | Very Good Partial Response (VGPR) | Baseline up to 5 years | The best overall response is defined as the sum proportion of subjects achieving stringent complete response (sCR), complete response (CR), and very good partial response (VGPR). or very good partial response (VGPR). |
| Secondary | Complete Response (CR) Rate | Baseline up to 5 years | The percentage of evaluable subjects who achieve complete response (CR). |
| Secondary | Duration of remission (DOR) | Baseline up to 5 years | The time from the first onset of objective response to the first documentation of disease progression or death from any cause, whichever occurs first. |
| Secondary | Time to first remission (TTR) | Baseline up to 5 years | The time from randomization to the first achievement of objective response. |
| Secondary | Negative rate of minimal residual disease (MRD) | Baseline up to 5 years | The proportion of subjects achieving MRD negativity. |
| Secondary | Overall survival (OS) | From randomization to death, the estimated evaluation period is up to 5 years | Time from randomization to death. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07569757
GET https://conductscience.org/api/trials/v1/NCT07569757/registered